Cancer-killing, decoy-resistant interleukin-18

Immunology and Cell Biology
Kyohei NakamuraMark J Smyth

Abstract

A recent paper by Zhou et al. describes a new engineered decoy-resistant interleukin-18 with potent antitumor activity and translational potential for cancer immunotherapy.

References

Nov 17, 2004·The Journal of Experimental Medicine·Mark J SmythYoshihiro Hayakawa
Aug 18, 2010·Current Medicinal Chemistry·S SrivastavaM J Robertson
Oct 12, 2013·Frontiers in Immunology·Charles A DinarelloGilles Kaplanski
Dec 31, 2014·Journal of Leukocyte Biology·Marina FabbiSilvano Ferrini
Aug 16, 2017·Cancer Cell·Alejandro López-SotoLorenzo Galluzzi
Aug 23, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Julius StraussJames L Gulley
Nov 11, 2018·British Journal of Cancer·Pedro BerraondoIgnacio Melero
Dec 12, 2018·Nature Reviews. Clinical Oncology·Jake S O'DonnellMark J Smyth
Jan 15, 2019·Trends in Immunology·Fernando Souza-Fonseca-GuimaraesNicholas D Huntington
Feb 6, 2020·The New England Journal of Medicine·Enli LiuKatayoun Rezvani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.